| Size | Price | Stock | Qty |
|---|---|---|---|
| 2g |
|
||
| 5g |
|
||
| 10g |
|
||
| 25g |
|
||
| Other Sizes |
|
Purity: ≥98%
Cefazolin sodium (cefazoline and cephazolin) is a 1st generation beta-lactam class of antibiotic used for the treatment of a number of bacterial infections. Specifically it is used to treat cellulitis, urinary tract infections, pneumonia, endocarditis, joint infection, and biliary tract infections. Cefazolin inhibits synthesis of bacterial cell wall by binding to and inactivating penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity, which results in the weakening of the bacterial cell wall and cell lysis.
| ln Vitro |
For lipopolysaccharide-stimulated C8-B4 cells, cefazolin sodium (0-300 μg/ml; 6 or 24 hours) exhibits a direct anti-inflammatory action [2]. Cell growth brought on by IL-2, IL-4, and IL-15 is inhibited when cefazolin sodium (0-400 μM) is applied for 72 hours [3]. The phosphorylation of JAK3 induced by IL-2, IL-4, IL-15, and IL-21 is inhibited by cefazolin sodium (0-400 μM; 30 minutes) treatment [3].
|
|---|---|
| ln Vivo |
Cefazolin sodium (subcutaneous injection; 300-500 mg/kg; once daily; 5 d) treatment can improve the postoperative learning and memory abilities of mice [2].
|
| Cell Assay |
Cell Viability Assay[2]
Cell Types: C8-B4 Cell Tested Concentrations: 0, 50, 100, 150, 200, 250 or 300 μg/ml Incubation Duration: 6 or 24 hrs (hours) Experimental Results: Complete inhibition of IL-1β with increasing doses, but The increase in IL-6 was inhibited only at 200 μg/ml. Cell proliferation assay[3] Cell Types: PBMC and TF-1 Cell Tested Concentrations: 0, 100, 200 and 400 μM Incubation Duration: 72 hrs (hours) Experimental Results: diminished cell proliferation induced by IL-2, IL-4 and IL-15, indicating Cefazolin not only interferes with IL-15Rα but also with IL-2/IL-15Rβ and/or γc. Cell viability assay [3] Cell Types: PBMC, NK-92 and TF-1 Cell Tested Concentrations: 0, 100, 200 and 400 μM Incubation Duration: 30 minutes Experimental Results: The phosphorylation of JAK3 was diminished after cytokine treatment, which was concluded to inhibit γc Receptor signal transduction. |
| Animal Protocol |
Animal/Disease Models: 6 to 8 weeks old male CD-1 mice underwent clinical exploratory laparotomy [2]
Doses: 300-500 mg/kg Route of Administration: subcutaneous injection; 300-500 mg/kg; one time/day; 5-day Experimental Results: Surgery-induced learning and memory dysfunction is attenuated. |
| Toxicity/Toxicokinetics |
Effects During Pregnancy and Lactation
◉ Summary of Use during Lactation Limited information indicates cefazolin produces low levels in milk that are not expected to cause adverse effects in breastfed infants. Occasionally disruption of the infant's gastrointestinal flora, resulting in diarrhea or thrush have been reported with cephalosporins, but these effects have not been adequately evaluated. Cefazolin is acceptable in nursing mothers. ◉ Effects in Breastfed Infants Relevant published information was not found as of the revision date. ◉ Effects on Lactation and Breastmilk Relevant published information was not found as of the revision date. |
| References | |
| Additional Infomation |
Cefazolin sodium is a cephalosporin organic sodium salt having [(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl and (1H-tetrazol-1-ylacetyl)amino side-groups. It contains a cefazolin(1-).
Cefazolin Sodium is the sodium salt of cefazolin, a beta-lactam antibiotic and first-generation cephalosporin with bactericidal activity. Cefazolin binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity, which results in the weakening of the bacterial cell wall and cell lysis. A semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine. See also: Cefazolin (has active moiety). |
| Molecular Formula |
C14H13N8NAO4S3
|
|---|---|
| Molecular Weight |
476.4890
|
| Exact Mass |
476.011
|
| CAS # |
27164-46-1
|
| Related CAS # |
Cefazolin;25953-19-9;Cefazolin sodium pentahydrate;115850-11-8
|
| PubChem CID |
23675322
|
| Appearance |
White to off-white solid powder
|
| Melting Point |
190 °C
|
| Index of Refraction |
20 ° (C=10, H2O)
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
30
|
| Complexity |
746
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CC1=NN=C(S1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)CN4C=NN=N4)SC2)C(=O)[O-].[Na+]
|
| InChi Key |
FLKYBGKDCCEQQM-WYUVZMMLSA-M
|
| InChi Code |
InChI=1S/C14H14N8O4S3.Na/c1-6-17-18-14(29-6)28-4-7-3-27-12-9(11(24)22(12)10(7)13(25)26)16-8(23)2-21-5-15-19-20-21/h5,9,12H,2-4H2,1H3,(H,16,23)(H,25,26)/q+1/p-1/t9-,12-/m1./s1
|
| Chemical Name |
sodium(6R,7R)-3-[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanylmethyl]-8-oxo-7-[[2-(tetrazol-1-yl)acetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
|
| Synonyms |
monosodium cephazolin Cefazolin sodium salt Sodium
cefazolin Sodium cephazolin Kefzol Sodium Cephazolin Sodium,
Cefazolin Sodium, Cephazolin Totacef
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ≥ 100 mg/mL (~209.87 mM)
DMSO : ~100 mg/mL (~209.87 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.25 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.25 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: 100 mg/mL (209.87 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0987 mL | 10.4934 mL | 20.9868 mL | |
| 5 mM | 0.4197 mL | 2.0987 mL | 4.1974 mL | |
| 10 mM | 0.2099 mL | 1.0493 mL | 2.0987 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA